• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by VectivBio Holding AG

    7/17/23 4:19:27 PM ET
    $VECT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $VECT alert in real time by email
    6-K 1 d451468d6k.htm 6-K 6-K

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 6-K

     

     

    Report of Foreign Private Issuer

    Pursuant to Rule 13a-16 or 15d-16

    Under the Securities Exchange Act of 1934

    For the month of July 2023

    Commission File Number 001-40316

     

     

    VECTIVBIO HOLDING AG

    (Exact name of registrant as specified in its charter)

     

     

    Aeschenvorstadt 36

    4051 Basel

    Switzerland

    (Address of principal executive offices)

     

     

    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

    Form 20-F  ☒            Form 40-F  ☐

     

     

     


    Amended Articles of Association

    On July 14, 2023, VectivBio Holding AG (the “Company”) registered with the commercial register of the Canton of Basel-Stadt its amended Articles of Association (the “Amended Articles”) reflecting the amendments thereto that were approved by the shareholders of the Company at the previously announced extraordinary general meeting of shareholders held on June  26, 2023. The description of the full slate of matters approved at the extraordinary general meeting is subject to and qualified in its entirety by reference to the Company’s Report on Form 6-K filed on June 26, 2023.

    A copy of the Company’s Amended Articles is filed as Exhibit 1.1 to this report on Form 6-K. The foregoing summary of the Amended Articles does not purport to be complete and is subject to, and qualified in its entirety by, the Amended Articles, which are filed herewith as Exhibit 1.1 and incorporated herein by reference.

    Officer Resignations

    In connection with the successful completion of Ironwood Pharmaceuticals, Inc.’s, a Delaware corporation (“Ironwood”), previously announced cash tender offer (the “Offer”) to acquire all of the outstanding registered ordinary shares, nominal value of CHF 0.05 per share, of the Company, at a price per share equal to $17.00, net to the seller in cash, without interest, and subject to deduction for any applicable withholding taxes, each of (i) Luca Santarelli, Chief Executive Officer of the Company, (ii) Claudia D’Augusta, Chief Financial Officer of the Company, (iii) Christian Meyer, Chief Operating Officer of the Company, (iv) Omar Khwaja, Chief Medical Officer of the Company, (v) Kevin Harris, Chief Commercial Officer of the Company, (vi) Scott Applebaum, Chief Legal Officer and Corporate Secretary of the Company, and (vii) Alain Bernard, Chief Technology Officer of the Company resigned from the Company or entered into customary separation or termination agreements with the Company.


    Exhibits

        
    1.1    Articles of Association of VectivBio Holding AG, as amended.


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

        VECTIVBIO HOLDING AG
    July 17, 2023     By:   /s/ Sravan K. Emany
          Sravan K. Emany
          Authorized Representative
    Get the next $VECT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VECT

    DatePrice TargetRatingAnalyst
    12/13/2022$18.00Buy
    Jefferies
    7/1/2022$23.00Overweight
    Piper Sandler
    More analyst ratings